WPA
TCRT icon

West Paces Advisors’s Alaunos Therapeutics TCRT Stock Holding History

West Paces Advisors’s Portfolio TCRT Stock Details TCRT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-10
Closed -$15 – 515
2025
Q1 		$15 Hold
10
– – ﹤0.01% 563
2024
Q4 		$19 Hold
10
– – ﹤0.01% 556
2024
Q3 		$32 Hold
10
– – ﹤0.01% 546
2024
Q2 		$70 Hold
10
– – ﹤0.01% 562
2024
Q1 		$181 Hold
10
– – ﹤0.01% 573
2023
Q4 		$106 Hold
10
– – ﹤0.01% 603
2023
Q3 		$198 Hold
10
– – ﹤0.01% 511
2023
Q2 		$765 Hold
10
– – ﹤0.01% 503
2023
Q1 		$945 Hold
10
– – ﹤0.01% 512
2022
Q4 		$974 Buy
+10
New +$1.45K ﹤0.01% 479

Other funds holding TCRT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
SPIA
Steward Partners Investment Advisory New York $19.6B AUM 22.89% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
CIBC Private Wealth Group
CIBC Private Wealth Group Atlanta, Georgia $59.2B AUM 20.62% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

West Paces Advisors's TCRT Position: Q2 2025 in Review

West Paces Advisors sold out of Alaunos Therapeutics (TCRT) in Q2 2025, closing a stake of 10 shares — an estimated $15 sold.

West Paces Advisors first reported a position in TCRT in Q4 2022 and held it in 10 quarters. The position peaked at $974 in Q4 2022. 28 funds tracked by Wall St. Rank hold TCRT as of Q2 2025.

  • West Paces Advisors reported no remaining Alaunos Therapeutics position as of Q2 2025 after selling out during the quarter.
  • West Paces Advisors sold 10 Alaunos Therapeutics shares in Q2 2025, an estimated $15.
  • West Paces Advisors first reported a position in Alaunos Therapeutics in Q4 2022 and held it in 10 quarters.
  • West Paces Advisors's Alaunos Therapeutics position peaked at $974 in Q4 2022.
  • 28 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q2 2025.

Based on West Paces Advisors's 13F filing for Q2 2025, filed 23 Jul 2025.